A unique offer
AN OFFER SIZED TO YOUR NEEDS
Collaborating with Institut Curie means having access to an offer tailored to your company size, to a network of high-level national and international experts, to the guarantee of confidentiality of your data and your project, and to different levels of partnership depending on your needs:
- Consulting and expertise
- Proof of concept or feasibility
- R&D collaboration
- Pre-market validation
- Joint R&D lab
|From therapeutic target to clinical validation|
Institut Curie conducts cancer research projects from preclinical to clinical studies in order to:
Researchers are organized in 12 joint research units grouped into 5 domains:
- Biology, Cancer, Genetics and Epigenetics
- Biology & Chemistry of Radiations, Cell Signaling and Cancer
- Integrative Tumour Biology, Immunology and Environment
- Multiscale Physics-Biology-Chemistry and cancer
- Translational research
They carry out scientific projects with high medical and innovative potential that will lead to significant improvements in patient's health and quality of life. Each year, innovative translational projects are carried out in immunotherapy, epigenetics, bioinformatics, protontherapy, etc.
Institut Curie is an international expert for eye cancers, pediatric tumors, breast cancers and sarcomas. We are currently participating in more than 20 clinical trials involving breast cancer. The paths of particular interest at present include:
- Precision medicine (characteristic biomarkers of the tumor)
- Targeted therapies (to block tumor cells more specifically)
- The development of new diagnostic methods (imaging techniques are being perfected)
- The detection of circulating tumor cells (for better monitoring of the disease’s evolution in its metastatic phase)
Our three sites in Paris region area welcome patients bearing cancers from the most frequent to the rarest, to improve their quality of life and offer them state-of-the-art treatments.
Institut Curie is at the forefront of innovation in radiotherapy. Our doctors offer radiotherapy for all types of cancers requiring this type of treatment thanks to one of the most efficient radiotherapy technical platforms in Europe. Doctors, medical physicists and researchers are constantly working together to innovate in radiotherapy and improve its effectiveness.
Institut Curie also has a strong history of commitment to immunology and immuno-oncology creating excellent interfaces for collaboration and interdisciplinary program development. In 2018, Institut Curie reached a new milestone with the creation of its Immunotherapy Center, the first of its kind in France and of international scope. This center is one of the major achievements of Institut Curie as part of its MC21 corporate project, bringing together researchers, doctors, patients and caregivers in one place.
Since 2003, Institut Curie has structured a Department of Translational Research intended to promote and facilitate translational research at the Institute. This department provides clinicians and researchers with human and technological resources enabling the development of application-oriented projects, with the objective of improving care for cancer patients (assessment and validation of diagnostic, prognostic and patient support tools, as well as development of biomedical devices or therapeutic approaches resulting from basic research).
A diverse range of projects is carried out with the help of the department: internal projects involving clinicians and researchers from the Institute, but also collaborative projects with other academic institutions or pharmaceutical/biotech companies. Some projects may also aim at providing expertise to the pharmaceutical and biotech industries or at creating “Proof of concept” for licensing and/or start-up creation.
Institut Curie provides a wide range of advanced technological platforms. Their services cover biological complexity from small molecules up to whole organisms and contribute to the progress of basic and translational research projects up to clinical studies.